This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pfizer (PFE) in Focus: Stock Moves 7.7% Higher
by Zacks Equity Research
Pfizer (PFE) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
4 Top-Ranked Energy Stocks to Scoop Up Post Monday's Rally
by Nilanjan Choudhury
DCP Midstream (DCP), Abraxas Petroleum (AXAS), Matador Resources (MTDR) and NuStar (NS) were up more than 10% yesterday with more gains ahead on a potential coronavirus treatment and revival in oil demand.
5 Blue-Chip Stocks to Buy on Coronavirus Vaccine Hope
by Nalak Das
A COVID-19 vaccine likely to benefit the Dow the most as it is more inclined toward cyclical stocks. Five among these are NIKE (NKE), Dow (DOW), The Procter & Gamble (PG), 3M (MMM) and Microsoft (MSFT).
5 ETFs Up Double Digits in a Day on Vaccine Optimism
by Sanghamitra Saha
Wall Street soared on Nov 9 on news that Pfizer (PFE) and BioNTech (BNTX) vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial.
2 Stocks to Watch on Pfizer's 90% Effective COVID-19 Vaccine
by Tirthankar Chakraborty
Pfizer's (PFE) shares hit an all-time high during yesterday's trading session on its milestone COVID-19 vaccine news, while Moderna's (MRNA) soared on optimism as it applies a similar technology.
More Foot-Traffic & Less Click-Traffic
by Daniel Laboe
Yesterday's hopeful vaccine news from Pfizer (PFE) and BioNTech (BNTX) has put a light at the end of the tunnel for value investors
More Foot-Traffic, Less Click-Traffic Pt. 2
by Daniel Laboe
It's day 2 of the market rotation out of secular growth and into beaten-down value names reversing 2020???s digitally-driven equity trend
Markets Rejoice Pfizer (PFE) Vaccine News
by Mark Vickery
For the month of November thus far, the Dow has already climbed more than 10%.
3 Highly-Ranked Large Cap Stocks to Buy Now
by Benjamin Rains
We explore three large-cap Zacks Rank #1 (Strong Buy) stocks that investors might want to buy right now that don't have to count on Pfizer's (PFE) vaccine progress...
The Sea Looks Calm: Global Week Ahead
by John Blank
This is not going to be an interesting week, relative to last week's exhausting line-up of major events. ??????That's OK with me. I expect it is OK with you, too.
Positive News on COVID-19 Vaccine
by Zacks Equity Research
Positive News on COVID-19 Vaccine
Pfizer's Covid Drug Proves 90%+ Effective; PFE, BNTX
by Mark Vickery
A Covid vaccine takes the lid off most everything market-related. That said, we're still looking at a period of months before it would be widely available.
What A Vaccine Means For The Stock Market
by Daniel Laboe
The markets are pricing in the end of the pandemic. This means more foot traffic and less click traffic.
Aerie (AERI) Q3 Loss Narrower Than Expected, Sales Rise Y/Y
by Zacks Equity Research
Aerie (AERI) reports a narrower-than-expected loss and revenues beat estimates in the third quarter of 2020.
Mylan's (MYL) Q3 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
Mylan (MYL) beats on Q3 earnings but misses on sales. The company is all set to merge with Pfizer's Upjohn business later in the month.
Bristol-Myers (BMY) Q3 Earnings Beat, '20 EPS View Raised
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the third quarter on strength of Revlimid and Eliquis.
Ionis (IONS) Misses Estimates for Q3 Earnings and Sales
by Zacks Equity Research
Ionis (IONS) posts wider-than-expected Q3 loss. Sales miss estimates.
AstraZeneca (AZN) Q3 Earnings Miss Estimates, Sales Beat
by Zacks Equity Research
AstraZeneca (AZN) lags Q3 earnings estimates and surpasses the same for sales. It maintains its financial outlook for the year.
Can Coronavirus Vaccine Efforts Aid BioNTech (BNTX) Q3 Earnings?
by Zacks Equity Research
On BioNTech's (BNTX) upcoming Q3 earnings call, investors' focus will be on the progress and advancement of its COVID-19 vaccine candidate, currently being developed in partnership with Pfizer.
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J
Mylan (MYL) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q3 results.
Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study
by Kinjel Shah
Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Novartis (NVS) and others release Q3 results
The Zacks Analyst Blog Highlights: UnitedHealth Group, Adobe, Pfizer, Intel and T-Mobile US
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth Group, Adobe, Pfizer, Intel and T-Mobile US
Glaxo (GSK) Q3 Earnings Top, Vaccines Segment on Recovery Path
by Zacks Equity Research
Glaxo (GSK) witnesses recovery in vaccinations rates in the third quarter. Performance of Pharmaceuticals and Consumer Healthcare businesses improve.
Top Research Reports for UnitedHealth, Adobe & Pfizer
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group (UNH), Adobe (ADBE) and Pfizer (PFE).